Comprehensive Prostate Fluid-Based Spectral Libraries for Enhanced Protein Detection in Urine.
Annie HaAmanda KhooVladimir IgnatchenkoShahbaz KhanMatthew WaasDanny VespriniStanley K LiuJulius O NyalwidheOliver John SemmesPaul C BoutrosThomas KislingerPublished in: Journal of proteome research (2024)
Biofluids contain molecules in circulation and from nearby organs that can be indicative of disease states. Characterizing the proteome of biofluids with DIA-MS is an emerging area of interest for biomarker discovery; yet, there is limited consensus on DIA-MS data analysis approaches for analyzing large numbers of biofluids. To evaluate various DIA-MS workflows, we collected urine from a clinically heterogeneous cohort of prostate cancer patients and acquired data in DDA and DIA scan modes. We then searched the DIA data against urine spectral libraries generated using common library generation approaches or a library-free method. We show that DIA-MS doubles the sample throughput compared to standard DDA-MS with minimal losses to peptide detection. We further demonstrate that using a sample-specific spectral library generated from individual urines maximizes peptide detection compared to a library-free approach, a pan-human library, or libraries generated from pooled, fractionated urines. Adding urine subproteomes, such as the urinary extracellular vesicular proteome, to the urine spectral library further improves the detection of prostate proteins in unfractionated urine. Altogether, we present an optimized DIA-MS workflow and provide several high-quality, comprehensive prostate cancer urine spectral libraries that can streamline future biomarker discovery studies of prostate cancer using DIA-MS.
Keyphrases
- prostate cancer
- mass spectrometry
- multiple sclerosis
- ms ms
- optical coherence tomography
- data analysis
- radical prostatectomy
- loop mediated isothermal amplification
- label free
- electronic health record
- real time pcr
- benign prostatic hyperplasia
- endothelial cells
- computed tomography
- clinical trial
- high throughput
- randomized controlled trial
- artificial intelligence
- binding protein
- contrast enhanced